The influence of frailty under direct oral anticoagulant use in patients with atrial fibrillation

Takashi Yamamoto,¹ Kentaro Yamashita,¹ Kiichi Miyamae,¹ Yuichiro Koyama,¹ Masataka Izumimoto,¹ Yoshihiro Kamimura,¹ Satoko Hayakawa,¹ Kazutaka Mori,¹ Takaaki Yamada,¹ Yasushi Tomita,¹ Toyoaki Murohara²

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/heartasia-2019-011212>).

¹Department of Cardiology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

²Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Correspondence to

Dr Kentaro Yamashita, Cardiology, National Hospital Organization Nagoya Medical Center, Nagoya 460-0001, Japan; yamaken2929@gmail.com

Received 12 March 2019

Revised 17 May 2019

Accepted 23 May 2019

ABSTRACT

Background Frailty is a prognostic factor in patients with atrial fibrillation (AF). However, there is no report on the associations between frailty and clinical adverse events in patients with AF taking direct oral anticoagulants (DOAC). The factors related to the occurrence of clinical adverse events are still under discussion. Therefore, we examined the associations between frailty and clinical adverse events in patients with AF taking DOAC in daily clinical practice.

Methods We retrospectively evaluated 240 consecutive patients with AF who had been newly prescribed DOAC in our hospital from April 2016 through May 2017. Data collected included Clinical Frailty Scale (CFS) scores, laboratory results and basic demographic information.

Results During the mean follow-up period of 13.4 months, 20 patients died (7.6 per 100 person-years), stroke or systemic embolism occurred in seven patients (2.6 per 100 person-years) and major bleeding occurred in 11 patients (4.2 per 100 person-years). We defined these adverse events as composite end points, and we estimated adjusted HRs and 95% CIs for risk factors using the Cox proportional hazard regression model. Frailty (defined as a CFS score of 5 or more; HR: 3.71; 95% CI: 1.59 to 8.65), female sex (HR: 3.49; 95% CI: 1.73 to 7.07), serum albumin level (HR: 0.47; 95% CI: 0.28 to 0.79) and malignancy (HR: 4.02; 95% CI: 1.83 to 8.84) were independent predictors of the composite end points.

Conclusions Frailty, female sex, hypoalbuminaemia and malignancy were associated with clinical adverse events in patients with AF who were prescribed DOAC.

INTRODUCTION

Both the number of elderly people and the prevalence of atrial fibrillation (AF) are increasing worldwide.^{1,2} Anticoagulation therapy for elderly patients with AF is important because of the high embolic risk in this population.³ The efficacy and safety of direct oral anticoagulants (DOAC) in patients with AF have been proven in large-scale clinical trials.^{4,5} The risk of bleeding or death is increased in elderly patients with AF.^{6–8} In addition, we sometimes observe cases in which clinically serious adverse events (eg, bleeding, stroke and death) occur over a short period of time after DOAC administration. However, it is not appropriate to dichotomise people solely based on age. Therefore, it remains controversial whether DOAC should be prescribed for this group.

In recent years, frailty status has drawn attention as being a strong predictor of mortality in elderly

Key questions

What is already known about this subject?

► Frailty is a prognostic factor in patients with atrial fibrillation (AF), but the associations between frailty and adverse events in direct oral anticoagulant (DOAC) users are poorly understood.

What does this study add?

► The incidence of adverse events (ie, all-cause mortality, stroke or systemic embolism and major bleeding) was high in patients with AF after DOAC administration. Furthermore, these events occurred over a median of 3.6 months (IQR: 1.3–9.3 months) in frail patients. Frailty is significantly associated with the incidence of adverse events than other proven risk factors.

How might this impact on clinical practice?

► In frail patients with AF, more careful follow-up of adverse events is necessary after DOAC administration.

people.⁹ There have also been reports that AF is associated with frailty.¹⁰ Frailty is a prognostic factor in patients with AF,¹¹ but to our knowledge, there are no reports on the prognostic potential of frailty in patients with AF who are taking DOAC. Therefore, we examined the associations between frailty and clinical adverse events in patients with AF taking DOAC in daily clinical practice.

MATERIALS AND METHODS

Study patients

Using the data warehouse and search functions of the electronic medical records (HOPE Life-Mark-HX, FUJITSU), we retrospectively evaluated 240 consecutive patients with AF who had been newly prescribed DOAC in our hospital from April 2016 through May 2017.

All patients were screened using the ICD-10 (the 10th revision of the International Statistical Classification of Diseases and Related Health Problems) code I48, and then AF was confirmed by an ECG or Holter ECG. Patients who had previously received anticoagulants including DOAC were excluded.

This study was conducted according to the Declaration of Helsinki and was approved by the Institutional Review Board of Nagoya Medical Centre.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Yamamoto T, Yamashita K, Miyamae K, et al. *Heart Asia* 2019;11:e011212. doi:10.1136/heartasia-2019-011212

Figure 1 Subject selection. AF, atrial fibrillation; DOAC, direct oral anticoagulant.

Data collection

Detailed patient characteristics including age, sex, past medical history, smoking history, blood pressure, body weight, prescription history and laboratory results were collected. To determine the CHA₂DS₂-VAsC (Cardiac failure or dysfunction, Hypertension, Age ≥ 75 [Doubled], Diabetes, Stroke [Doubled]-Vascular disease, Age 65–74 and Sex category [Female]) score, points were assigned to each of the following conditions, and the sum was calculated: congestive heart failure, hypertension, age (patients aged ≥ 75 years received two points and patients aged 65–74 years received one point), diabetes mellitus, vascular disease, female sex and prior stroke or transient ischaemic attack (TIA; two points).¹² We included a history of hypertension, rather than blood pressure greater than 160 mm Hg, because even well-controlled hypertension is an independent risk factor for stroke.¹³ Diabetes mellitus was defined as a fasting plasma glucose concentration >126 mg/dL and/or a glycosylated haemoglobin concentration $\geq 6.5\%$ (National Glycohemoglobin Standardisation Programme), or intake of any antidiabetic agents. Current and ex-smokers were defined as ‘smoker’. The estimated glomerular filtration rate (eGFR) was calculated using the equation for Japanese subjects recommended by the Japanese Society of Nephrology: $\text{eGFR (mL/min/1.73 m}^2\text{)} = 194 \times \text{SCr}^{-1.094} \times \text{Age}^{-0.287} \times 0.739$ (if female).¹⁴ Cancer was defined as malignancy diagnosed within the previous 6 months; recurrent, regionally advanced or metastatic cancer; cancer for which treatment had been administered within 6 months prior to DOAC prescription; or haematological cancer that was not in complete remission.

Clinical Frailty Scale

The Clinical Frailty Scale (CFS) was developed and validated by Rockwood *et al.*¹⁵ Patients are assigned a score of 1–9 (1: very fit; 2: well; 3: managing well; 4: vulnerable; 5: mildly frail; 6: moderately frail; 7: severely frail; 8: very severely frail and 9: terminally ill) based on a semiquantitative evaluation of their symptoms, level of inactivity, exhaustion and basic or instrumental activities of daily living. CFS scores were determined by trained physicians based on the records of nurses who directly met with each patient. Patients were classified into one of two categories based on CFS scores: frail (a score of 5–9) or non-frail (a score of 1–4).

Clinical outcomes

Follow-up patient data were obtained from the medical records on 2 May 2019. We defined all-cause mortality, stroke or systemic embolism (SE) confirmed by imaging, or major bleeding that

occurred during the follow-up period as composite end points. Major bleeding was defined as a reduction in haemoglobin by at least 2 g/dL, transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ using definitions set out by The International Society on Thrombosis and Haemostasis.¹⁶

Statistical analyses

Categorical data are presented as percentages (%), and consecutive patient data are presented as mean $\pm$ SD or median (range), depending on their distribution. We compared categorical variables using the χ^2 test when appropriate; otherwise, we used Fisher’s exact test. We compared continuous variables using the Student’s or Welch’s t-test on the basis of the dispersion when appropriate; otherwise, we used the Mann-Whitney U test on the basis of distribution. The incidence rate of each composite end point was calculated as the number per 100 person-years with 95% CIs. A Cox proportional hazards regression analysis was used to assess the association between factors and composite end points. Any statistically significant covariates (ie, $p < 0.05$) in the univariate analysis were included in the multivariate analysis using a downward stepwise regression method. The thresholds for entry and removal were 0.05 and 1.0, respectively. We also analysed the incidence rate of the composite end points in each group stratified by frailty status as determined using CFS scores (frail: 5–9; and non-frail: 1–4), and assessed the difference between them using a log-rank test. All statistical analyses were done using JMP V.9.0 (SAS Institute, Cary, NC, USA), and all tests were two-tailed with the statistical significance set at $p < 0.05$.

RESULTS

We enrolled 240 patients, as shown in figure 1. Table 1 shows the baseline characteristics of these patients. The mean age of the patients was 76.1 ± 10.0 years and 42.9% of them were women. The median CHA₂DS₂-VAsC score was 4, and the median HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalization ratio, Elderly (>65 years), Drug/alcohol concomitantly) score was 2. An under-dose of DOAC was observed in 8.33% of patients. The median eGFR and serum albumin level were 63.8 mL/min/1.73 m² and 3.60 g/dL, respectively. Frail patients constituted 50.0% of the total patient population.

The frail group had a higher proportion of women (55.8% vs 30.0%; $p < 0.001$), and was older (81.2 ± 7.9 years vs 71.0 ± 10.0 years; $p < 0.001$) and lighter in weight (52.5 kg vs 60.5 kg; $p < 0.001$), compared with the non-frail group. The median CFS (6 vs 3; $p < 0.001$), CHA₂DS₂-VAsC score (5 vs 3; $p < 0.001$) and HAS-BLED score (2 vs 1; $p < 0.001$) were higher in frail group compared with the non-frail group. History of stroke was more common in the frail group (58.3% vs 27.5%; $p < 0.001$). Serum albumin (3.3 g/dL vs 4.0 g/dL; $p < 0.001$) and haemoglobin (12.3 mg/dL vs 13.7 mg/dL; $p < 0.001$) levels were lower in the frail group.

During the median follow-up period of 9.2 months (IQR: 1.5–25.5 months), seven patients had a stroke or SE, 11 had a major bleed and 20 died. In total, 37 patients had a composite end point event (14.0 per 100 person-years). The incidence of stroke or SE, major bleeding, all-cause mortality, and stroke, SE or all-cause mortality in the frail group were 6.2 per 100 person-years, 8.3 per 100 person-years, 16.6 per 100 person-years and 30.2 per 100 person-years, respectively (table 2).

In the univariate analysis, age, female sex, weight, heart failure, haemoglobin, serum albumin, frailty, malignancy,

Table 1 Baseline characteristics of the patients

Characteristics	Total (n=240)	Frail (n=120)	Non-frail (n=120)	P value*
Female, n (%)	103 (42.9)	67 (55.8)	36 (30.0)	<0.001
Age, years	76.1±10	81.2±7.8	71.0±10	<0.001
Weight, kg	57.0 (48.4–64.9)	52.5 (44.3–60.0)	60.5 (53.5–67.0)	<0.001
CFS	4.5 (3.0–6.0)	6.0 (6.0–7.0)	3.0 (3.0–4.0)	<0.001
Hypertension, n (%)	147 (61.3)	78 (65.0)	69 (57.5)	0.233
Diabetes mellitus, n (%)	42 (17.5)	22 (18.3)	20 (16.7)	0.734
Smoking, n (%)	118 (49.2)	49 (40.8)	69 (57.5)	0.010
Heart failure, n (%)	101 (42.1)	53 (44.2)	48 (40.0)	0.513
Bleeding history, n (%)	14 (5.8)	9 (7.5)	5 (4.2)	0.271
Stroke/TIA, n (%)	103 (42.9)	70 (58.3)	33 (27.5)	<0.001
Paroxysmal AF, n (%)	126 (52.9)	56 (46.7)	70 (58.3)	0.070
CHA ₂ DS ₂ -VAsC score	4 (3–5)	5 (4–6)	3 (2–4)	<0.001
HAS-BLED score	2 (1–2)	2 (1–2)	1 (1–2)	<0.001
BUN (mg/dL)	17 (13–21)	17 (12–21)	16 (13–20)	0.855
eGFR (mL/min/m ²)	63.8 (51.7–78.1)	67.0 (51.8–82.6)	62.7 (51.7–72.0)	0.124
Albumin (g/dL)	3.6 (3.1–4.0)	3.3 (2.7–3.7)	4.0 (3.5–4.2)	<0.001
Hb (mg/dL)	12.9 (11.2–14.2)	12.3 (10.7–13.3)	13.7 (12.2–14.7)	<0.001
DOAC under-dosed (%)	20 (8.3)	8 (6.7)	12 (10)	0.350
DOAC over-dosed (%)	13 (5.4)	5 (4.2)	8 (6.7)	0.392
β-blocker, n (%)	118 (49.2)	56 (46.7)	62 (51.7)	0.439
ACE-I/ARB, n (%)	87 (36.3)	38 (31.7)	49 (40.8)	0.140
Mineralocorticoid receptor antagonist, n (%)	37 (15.4)	23 (19.2)	14 (11.7)	0.108
Antiplatelet drugs, n (%)	39 (16.3)	19 (15.8)	20 (16.7)	0.861
Malignancy, n (%)	20 (8.3)	13 (10.8)	7 (5.8)	0.161

Values are presented as mean±SD, median (IQR) or n (%).

*P value for comparison between frail and non-frail from log-rank test.

ACE-I, ACE inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BUN, blood urea nitrogen; CFS, Clinical Frailty Scale; DOAC, direct oral anticoagulants; TIA, transient ischaemic attack; eGFR, estimated glomerular filtration rate.

CHA₂DS₂-VAsC score and HAS-BLED score were significantly associated with the composite end points. In the multivariate analysis, frailty (HR: 3.71, 95% CI: 1.59 to 8.65), female sex (HR: 3.49, 95% CI: 1.73 to 7.07), serum albumin level (HR: 0.47, 95% CI: 0.28 to 0.79) and malignancy (HR: 4.02, 95% CI: 1.83 to 8.84) were confirmed as statistically significant factors associated with an increased risk of the composite end points (table 3). The Kaplan-Meier curves stratified by frailty category are shown in figure 2. The cumulative incidence rate was significantly higher in the frail group compared with the non-frail group (log-rank test; p<0.001).

Table 2 Incidence of clinical events during follow-up (per 100 person-years)

	Total (n=240)	Frail (n=120)	Non-frail (n=120)	P value*
Stroke/SE/Major bleeding /all-cause mortality	14.0	30.2	4.8	<0.001
Stroke/SE	2.6	6.2	0.6	0.024
Major bleeding	4.2	8.3	1.8	0.038
All-cause death	7.6	16.6	2.4	<0.001
Cardiac death	1.5	2.1	1.2	0.583
Non-cardiac death	6.0	14.6	1.2	<0.001

Frail, CFS 5–9; non-frail, CFS 1–4.

*P value for comparison between frail and non-frail from log-rank test.

CFS, Clinical Frailty Scale; SE, systemic embolism.

DISCUSSION

In this study, frailty, hypoalbuminaemia, female sex and malignancy were associated with a higher incidence rate of the composite end points, which included all-cause mortality, stroke or SE, and/or major bleeding. The incidence rate of the composite end points was high and many patients had events shortly after DOAC administration (the median number of months before the occurrence of an adverse event was 5.5 (IQR: 1.8–11.5) months in all patients, and 3.6 (IQR: 1.3–9.3) months in the frail patient group).

In a previous cohort study of Japanese patients with AF, the incidence rate of adverse events (death or stroke/SE) was 8.7 per 100 person-years.¹⁷ In addition, when the previous study focused on patients weighing less than 50 kg, the incidence rate of adverse events increased to 16.1 per 100 person-years.¹⁷ In our study, 50% of patients were frail and their mean body weight was 52.5 kg, so the incidence rate observed in this study was not surprising. Furthermore, the incidence rate of non-cardiovascular events was also consistent with past reports (eg, cardiac death in 1.1 per 100 person-years, non-cardiac death in 5.7 per 100 person-years¹⁷ and 66% of patients dying due to non-cardiovascular events¹⁸). Although the median CHA₂DS₂-VAsC score in the frail group was 5 and the incidence of stroke or other thromboembolic events was expected to be 6.7% per year,¹² ischaemic stroke occurred in 6.2% of frail patients. In addition, although the median HAS-BLED score in the frail group was 2 and the incidence of major bleeding was expected to be 1.88% per year,¹⁹ major bleeding occurred in 8.3% of frail patients. Therefore, it is possible that death and bleeding act as competing events against the decrease in incidence of cerebral infarction in our study. In the frail group, we found that non-cardiac death

Table 3 Indicators of Stroke/Systolic Embolism/Major Bleeding/All-Cause Mortality

Factor	Univariate			Multivariate		
	HR	95% CI	P value	HR	95% CI	P value
Age	1.08	1.04 to 1.13	<0.001	-	-	-
Female	3.36	1.71 to 6.62	<0.001	3.49	1.73 to 7.07	0.001
Weight	0.96	0.93 to 0.99	0.004	-	-	-
Hypertension	2.00	0.94 to 4.24	0.067	-	-	-
Diabetes mellitus	0.67	0.26 to 1.73	0.408	-	-	-
Heart failure	2.25	1.17 to 4.33	0.012	-	-	-
Stroke/TIA	1.43	0.75 to 2.73	0.274	-	-	-
Bleeding history	1.93	0.59 to 6.30	0.270	-	-	-
eGFR	0.99	0.98 to 1.01	0.348	-	-	-
Hb	0.73	0.62 to 0.86	<0.001	-	-	-
Albumin	0.40	0.26 to 0.63	<0.001	0.47	0.28 to 0.79	0.005
Frail	5.72	2.60 to 12.6	<0.001	3.71	1.59 to 8.65	0.002
Malignancy	3.37	1.59 to 7.16	0.001	4.02	1.83 to 8.84	0.001
Under-dosed	2.46	0.74 to 8.23	0.130	-	-	-
Over-dosed	0.57	0.08 to 4.16	0.574	-	-	-
CHA ₂ DS ₂ -VASc score	1.41	1.17 to 1.71	<0.001	-	-	-
HAS-BLED score	1.57	1.12 to 2.20	0.009	-	-	-

Frail: CFS score of 5–9.

Hb, haemoglobin; TIA, transient ischaemic attack; eGFR, estimated glomerular filtration rate.

increased significantly compared with the non-frail group. In past reports, mortality due to undetermined cause increased substantially in accordance with age, and non-cardiovascular death was most strongly associated with anaemia.²⁰ This report may indicate that more careful follow-up of major bleeding events is necessary after DOAC administration in older patients.

Frailty is a complex syndrome of decreased stress tolerance that arises from impairments in multiple organ systems, and it is considered a factor in the difference between biological and chronological age.⁹ In general, frailty leads to a higher risk of disability, hospital admission and death,²¹ and this higher risk has been reported in patients with AF.¹¹ In this study, it is interesting that frailty remained a risk factor for the composite end points despite accounting for established risk factors such as age,

CHA₂DS₂-VASc score and HAS-BLED score in the multivariate analysis. On the contrary, there is also a report that AF is associated with frailty,¹⁰ and it is possible that stress tolerance had become considerably low in these frail patients at the time of AF development. Therefore, frailty could be a strong indicator of these adverse events in patients with AF.

Previous studies have reported that hypoalbuminaemia is an important marker of clinical adverse events such as major bleeding and death,²² and our study had similar results. Hypoalbuminaemia has several aetiologies that include decreased synthesis in the liver, lack of intake, systemic inflammation and loss of albumin (nephritic syndrome or protein-losing enteropathy).²³ However, a detailed pathophysiological mechanism has not been proposed to explain the association between hypoalbuminaemia and clinical events. An association between hypoalbuminaemia and frailty has also been reported.²⁴ However, the pathophysiology underlying the relationship between hypoalbuminaemia and frailty is also unclear. The presence of a third factor that can affect both hypoalbuminaemia and frailty has been suggested and includes a decrease in muscle mass,²⁵ poor dietary intake and chronic inflammation.²⁶ In our study, we did not measure muscle mass, dietary intake or inflammatory markers, so we could not determine the detailed relationship between hypoalbuminaemia and frailty.

Past reports have also associated with anaemia with frailty,²⁷ and anaemia has been associated with clinical adverse events in patients with AF.²⁸ In this study, univariate analysis showed that anaemia was significantly associated with the composite end points, but the multivariate analysis did not show this significant association. Therefore, it may be clinically important to comprehensively understand the patient's condition instead of only evaluating haemoglobin levels. In patients not eligible for randomised controlled trials after starting DOAC, more careful follow-up is necessary, and a more comprehensive approach is required.⁹

Contrary to existing evidence, stroke or TIA and bleeding history were not predictive of composite end points in the univariate analysis in our study. Bleeding history was an indicator

Figure 2 Event-free survival curve for stroke/systemic embolism/major bleeding according to frailty status. CFS, Clinical Frailty Scale

of major bleeding, but not stroke or SE.⁷ This could explain why major bleeding was not a predictor of composite end points. In our study, bleeding history was a predictor of major bleeding in the univariate analysis (HR: 4.70, 95% CI: 1.00 to 22.1). Stroke or TIA history is also a predictor of stroke, but not a significant predictor of major bleeding.⁷ Moreover, our hospital actively performs emergent endovascular treatment of acute ischaemic stroke (about 60 cases a year). These factors may explain why stroke or TIA history was not predictive of composite end points in our study.

Our study has some limitations. First, this study had a small sample size. Second, this study was a retrospective single-centre study, and we could not determine causality. Further studies are needed to address whether improvement in frailty leads to a reduced risk of adverse events in patients with AF. Third, there are several other methods that may be used to evaluate frailty status.²⁹ In clinical practice, CFS is superior in its simplicity, and several studies have used this scale score as a prognostic factor for adverse events.³⁰ Fourth, follow-up periods were short. Fifth, patients who did not receive DOAC were not studied.

CONCLUSIONS

Frailty, hypoalbuminaemia, female sex and malignancy were associated with clinical adverse events in patients with AF who were prescribed DOAC.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

REFERENCES

- Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. *Circulation* 2014;129:837–47.
- Lim CW, Kasim S, Ismail JR, et al. Prevalence of atrial fibrillation in the Malaysian communities. *Heart Asia* 2016;8:62–6.
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. *Stroke* 1991;22:983–8.
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2013;369:2093–104.
- Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;365:981–92.
- Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the engage AF–TIMI 48 trial. *J Am Heart Assoc* 2016;5.
- Yamashita Y, Uozumi R, Hamatani Y, et al. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients - Fushimi AF Registry. *Circ J* 2017;81:1278–85.
- Yamashita Y, Hamatani Y, Esato M, et al. Clinical Characteristics and Outcomes in Extreme Elderly (Age $\geq$ 85 Years) Japanese Patients With Atrial Fibrillation: The Fushimi AF Registry. *Chest* 2016;149:401–12.
- Singh M, Stewart R, White H. Importance of frailty in patients with cardiovascular disease. *Eur Heart J* 2014;35:1726–31.
- Fumagalli S, Tarantini F, Guarducci L, et al. Atrial fibrillation is a possible marker of frailty in hospitalized patients: results of the GIFA study. *Aging Clin Exp Res* 2010;22:129–33.
- Kim S-W, Yoon S-J, Choi J-Y, et al. Clinical implication of frailty assessment in older patients with atrial fibrillation. *Arch Gerontol Geriatr* 2017;70:1–7.
- Lip GYH, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. *Stroke* 2010;41:2731–8.
- D'Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham study. *Stroke* 1994;25:40–3.
- Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* 2009;53:982–92.
- Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. *CMAJ* 2005;173:489–95.
- Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, et al. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. *J Thromb Haemost* 2005;3:692–4.
- Hamatani Y, Ogawa H, Uozumi R, et al. Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients - Insight From the Fushimi AF Registry. *Circ J* 2015;79:1009–17.
- Fauchier L, Samson A, Chaize G, et al. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. *Open Heart* 2015;2:e000290.
- Pisters R, Lane DA, Nieuwlaar R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010;138:1093–100.
- An Y, Ogawa H, Yamashita Y, et al. Causes of death in Japanese patients with atrial fibrillation: the Fushimi atrial fibrillation registry. *Eur Heart J Qual Care Clin Outcomes* 2019;5:35–42.
- Wallis SJ, Wall J, Biram RWS, et al. Association of the clinical frailty scale with hospital outcomes. *QJM* 2015;108:943–9.
- Corona LP, de Oliveira Duarte YA, Lebrão ML. Markers of nutritional status and mortality in older adults: the role of anemia and hypoalbuminemia. *Geriatr Gerontol Int* 2018;18:177–82.
- Kim S, McClave SA, Martindale RG, et al. Hypoalbuminemia and clinical outcomes: what is the mechanism behind the relationship? *Am Surg* 2017;83:1220–7.
- Okamura T, Hayakawa T, Hozawa A, et al. Lower levels of serum albumin and total cholesterol associated with decline in activities of daily living and excess mortality in a 12-year cohort study of elderly Japanese. *J Am Geriatr Soc* 2008;56:529–35.
- Visser M, Kritchevsky SB, Newman AB, et al. Lower serum albumin concentration and change in muscle mass: the health, aging and body composition study. *Am J Clin Nutr* 2005;82:531–7.
- Fontana L, Addante F, Copetti M, et al. Identification of a metabolic signature for multidimensional impairment and mortality risk in hospitalized older patients. *Aging Cell* 2013;12:459–66.
- Roy CN. Anemia in frailty. *Clin Geriatr Med* 2011;27:67–78.
- Sharma S, Gage BF, Deych E, et al. Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. *Am Heart J* 2009;157:1057–63.
- Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. *Clin Geriatr Med* 2011;27:17–26.
- Shimura T, Yamamoto M, Kano S, et al. Impact of the clinical frailty scale on outcomes after transcatheter aortic valve replacement. *Circulation* 2017;135:2013–24.